Evidence map›Paper›PMID 37367600›Full record

ArticleJournal of fungi (Basel, Switzerland)2023

Clorgyline Analogs Synergize with Azoles against Drug Efflux in

Stephanie Toepfer, Michaela Lackner, Mikhail V Keniya, Lisa-Maria Zenz, Marianne Friemert, Franz Bracher, Brian C Monk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Functional characterization ofFrontiers in microbiology · 2026
    Article
  2. Article
  3. The multidrug-resistantCurrent research in microbial sciences · 2025
    Review
  4. Review
  5. Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Stephanie ToepferSir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin 9016, New Zealand.
Michaela LacknerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0001-9073-2886
Mikhail V KeniyaSir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin 9016, New Zealand.
Lisa-Maria ZenzInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Marianne FriemertCenter for Drug Research, Department of Pharmacy, Ludwig-Maximilian University of Munich, 81377 Munich, Germany.
Franz BracherCenter for Drug Research, Department of Pharmacy, Ludwig-Maximilian University of Munich, 81377 Munich, Germany.ORCID 0000-0003-0009-8629
Brian C MonkSir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0003-2264-3480
Innsbruck Medical University · ATLudwig-Maximilians-Universität München · DEUniversity of Otago · NZHackensack Meridian Health · US

Funding

Health Research Council of New Zealand 19/397
6 · The paper itself

Abstract

Concern about the global emergence of multidrug-resistant fungal pathogens led us to explore the use of combination therapy to combat azole resistance in

Indexed as

antifungalCandida aurisCdr1checkerboard assaycombination therapyefflux pumpsheterologous expression systemMdr1multidrug resistancenovel therapySaccharomyces cerevisiaeyeast pathogen

Identifiers

PMID37367600
PMCPMC10303049
OpenAlexW4380686319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.